HERA Indicates that Adjuvant Trastuzumab Confers Equal Benefit for HER2-Positive Invasive Ductal and Invasive Lobular Breast Cancers

April 15, 2013

This Podcast reviews the results of the analysis conducted by Metzger-Filho et al. regarding the benefit of trastuzumab for patients with invasive lobular breast cancer treated on the Herceptin Adjuvant Trial (HERA) and provides perspective regarding the clinical significance of these findings.